BRCA1 and familial ovarian cancer: Testing women for the panel of population-specific recurrent/founder mutations may be a valuable approach for therapy decisions in ovarian cancer patients (i.e., platinum or PARP inhibitors in BRCA1/2 carriers) or for preventing hereditary ovarian cancer.